has been cited by the following article(s):
[1]
|
Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer
Pharmacology & Therapeutics,
2020
DOI:10.1016/j.pharmthera.2019.107437
|
|
|
[2]
|
MicroRNAs in ovarian follicular atresia and granulosa cell apoptosis
Reproductive Biology and Endocrinology,
2019
DOI:10.1186/s12958-018-0450-y
|
|
|
[3]
|
Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents
Drug Discovery Today,
2019
DOI:10.1016/j.drudis.2019.02.003
|
|
|
[4]
|
Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors
Cancers,
2019
DOI:10.3390/cancers11101530
|
|
|
[5]
|
Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review
Drug Development Research,
2015
DOI:10.1002/ddr.21268
|
|
|
[6]
|
Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review
Drug Development Research,
2015
DOI:10.1002/ddr.21268
|
|
|